Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance DOI Creative Commons
Jing Wang, Baizhou Li, Meng Luo

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: April 3, 2024

Abstract Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25–60% DCIS progress to invasive ductal (IDC). The challenge lies distinguishing between non-progressive and progressive DCIS, often resulting over- or under-treatment many cases. With increasing screen-detected these years, the nature of has aroused worldwide attention. A deeper understanding biological molecular journey DCIS-IDC transition is crucial for more effective clinical management. Here, we reviewed key signaling pathways cancer that may contribute initiation progression. We also explored features IDC, shedding light on progression through both inherent changes within tumor cells alterations microenvironment. addition, valuable research tools utilized studying including preclinical models newer advanced technologies such as single-cell sequencing, spatial transcriptomics artificial intelligence, have been systematically summarized. Further, thoroughly discussed advancements prognostic biomarkers managements, with aim facilitating personalized treatment strategies future. Research already yielded significant insights into carcinogenesis will continue pave way practical applications.

Language: Английский

The microenvironment in breast cancer progression: biology and implications for treatment DOI Creative Commons
Andrew E. Place,

Sung Jin Huh,

Kornélia Polyák

et al.

Breast Cancer Research, Journal Year: 2011, Volume and Issue: 13(6)

Published: Nov. 1, 2011

Breast cancer comprises a heterogeneous group of malignancies derived from the ductal epithelium. The microenvironment these cancers is now recognized as critical participant in tumor progression and therapeutic responses. Recent data demonstrate significant gene expression epigenetic alterations cells composing during disease progression, which can be explored biomarkers targets for therapy. Indeed, signatures stroma have been linked to clinical outcomes. There increasing interest translating our current understanding development novel therapies.

Language: Английский

Citations

397
Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer DOI Open Access
So Yeon Park,

Hee Eun Lee,

Hailun Li

et al.

Clinical Cancer Research, Journal Year: 2010, Volume and Issue: 16(3), P. 876 - 887

Published: Jan. 27, 2010

Abstract Purpose: To evaluate the expression of stem cell–related markers at cellular level in human breast tumors different subtypes and histologic stage. Experimental Design: We performed immunohistochemical analyses 12 proteins [CD44, CD24, ALDH1, vimentin, osteonectin, EPCR, caveolin 1, connexin 43, cytokeratin 18 (CK18), MUC1, claudin 7, GATA3] selected based on their differential cancer cells with more differentiated cell–like characteristics 47 cases invasive ductal carcinoma (IDC) only, 135 IDC situ (DCIS), 35 DCIS microinvasion, 58 pure DCIS. also analyzed 73 IDCs adjacent to determine differences by histology within individual tumors. CD44+/CD24− CD24−/CD24+ were detected using double immunohistochemistry. Results: CD44 EPCR was among four groups lower compared tumors, especially luminal A subtype. The CK18, GATA3, MUC1 differed tumor subtype some groups. ALDH1-positive frequent basal-like HER2+ than 69% all 100% 52% having these cells. Conclusions: Our findings suggest that cancer, frequency positive for cell varies according Clin Cancer Res; 16(3); 876–87

Language: Английский

Citations

391
The Regulatory Role of MicroRNAs in Breast Cancer DOI Open Access

Hui-Yi Loh,

Brendan P. Norman, Kok‐Song Lai

et al.

International Journal of Molecular Sciences, Journal Year: 2019, Volume and Issue: 20(19), P. 4940 - 4940

Published: Oct. 6, 2019

MicroRNAs (miRNAs) are small non-coding RNA molecules which function as critical post-transcriptional gene regulators of various biological functions. Generally, miRNAs negatively regulate expression by binding to their selective messenger RNAs (mRNAs), thereby leading either mRNA degradation or translational repression, depending on the degree complementarity with target sequences. Aberrant these has been linked etiologically human diseases including breast cancer. Different cellular pathways cancer development such cell proliferation, apoptotic response, metastasis, recurrence and chemoresistance regulated oncogenic miRNA (oncomiR) tumor suppressor (tsmiR). In this review, we highlight current state research into involved in cancer, particular attention articles published between years 2000 2019, using detailed searches databases PubMed, Google Scholar, Scopus. The regulatory roles dysregulated potential therapeutic targets also discussed.

Language: Английский

Citations

290
Triple‐negative breast cancer: Present challenges and new perspectives DOI
Franca Podo,

L.M.C. Buydens,

Hadassa Degani

et al.

Molecular Oncology, Journal Year: 2010, Volume and Issue: 4(3), P. 209 - 229

Published: April 24, 2010

Language: Английский

Citations

289
Molecular and Cellular Heterogeneity in Breast Cancer DOI Creative Commons

Ashley G. Rivenbark,

Siobhán O’Connor, William B. Coleman

et al.

American Journal Of Pathology, Journal Year: 2013, Volume and Issue: 183(4), P. 1113 - 1124

Published: Aug. 28, 2013

Breast cancer is noted for disparate clinical behaviors and patient outcomes, despite common histopathological features at diagnosis. Molecular pathogenesis studies suggest that breast a collection of diseases with variable molecular underpinnings modulate therapeutic responses, disease-free intervals, long-term survival. Traditional strategies individual patients are guided by the expression status estrogen progesterone receptors (ER PR) human epidermal growth factor receptor 2 (HER2). Although such methods classification have utility in selection targeted therapies, short-term responses survival remain difficult to predict. signatures based on complex gene patterns prediction but not yet used guiding therapy. Examination correspondence between these reveals lack agreement affecting significant percentage cases. To realize true personalized therapy, more complete analysis evaluation characteristics disease required, together an understanding contributions specific genetic epigenetic alterations (and their combinations) management patient. Here, we discuss cellular heterogeneity cancer, impact this practical classification, challenges treatment.

Language: Английский

Citations

272
Cancer overdiagnosis: a biological challenge and clinical dilemma DOI
Sudhir Srivastava, Eugene J. Koay, Alexander D. Borowsky

et al.

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 19(6), P. 349 - 358

Published: April 25, 2019

Language: Английский

Citations

271
Insight into the heterogeneity of breast cancer through next-generation sequencing DOI Open Access
Hege G. Russnes, Nicholas Navin, James Hicks

et al.

Journal of Clinical Investigation, Journal Year: 2011, Volume and Issue: 121(10), P. 3810 - 3818

Published: Oct. 3, 2011

Rapid and sophisticated improvements in molecular analysis have allowed us to sequence whole human genomes as well cancer genomes, the findings suggest that we may be approaching ability individualize diagnosis treatment of cancer. This paradigmatic shift approach will require clinicians researchers overcome several challenges including huge spectrum tumor types within a given cancer, cell-to-cell variations observed tumors. review discusses how next-generation sequencing breast already reveals insight into heterogeneity it can contribute future classification management.

Language: Английский

Citations

249
Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives DOI Creative Commons
Nicholas A. Saunders, Fiona Simpson, Erik W. Thompson

et al.

EMBO Molecular Medicine, Journal Year: 2012, Volume and Issue: 4(8), P. 675 - 684

Published: June 25, 2012

Abstract Drug resistance continues to be a major barrier the delivery of curative therapies in cancer. Historically, drug has been associated with over‐expression transporters, changes kinetics or amplification targets. However, emergence patients treated new‐targeted provided new insight into complexities underlying cancer resistance. Recent data now implicate intratumoural heterogeneity as driver Single cell sequencing studies that identified multiple genetically distinct variants within human tumours clearly demonstrate heterogeneous nature tumours. The contributors are (i) genetic variation, (ii) stochastic processes, (iii) microenvironment and (iv) tissue plasticity. Each these factors impacts on sensitivity. To deliver patients, modification current therapeutic strategies include methods estimate plasticity will essential.

Language: Английский

Citations

243
Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells DOI
Qi Xie, Qian Bai, Lingyun Zou

et al.

Genes Chromosomes and Cancer, Journal Year: 2014, Volume and Issue: 53(5), P. 422 - 431

Published: Feb. 16, 2014

It has been previously demonstrated that genistein exhibits anticancer activity against breast cancer. However, the precise mechanisms underlying effect of genistein, in particular epigenetic basis, remain unclear. In this study, we investigated whether could modulate DNA methylation status and expression cancer‐related genes cancer cells. We treated MCF‐7 MDA‐MB‐231 human cells with vitro. found decreased levels global methylation, methyltransferase (DNMT) DNMT1 . Yet, DNMT3A DNMT3B showed no significant change. Using molecular modeling, observed might directly interact catalytic domain DNMT1, thus competitively inhibiting binding hemimethylated to DNMT1. Furthermore, promoter region multiple tumor suppressor (TSGs) such as ataxia telangiectasia mutated ( ATM ), adenomatous polyposis coli APC phosphatase tensin homolog PTEN mammary serpin peptidase inhibitor SERPINB5 increased mRNA these genes. detected changes or stratifin SFN ). These results suggest on may be partly due its ability demethylate reactivate methylation‐silenced TSGs through direct interaction inhibition expression. © 2014 Wiley Periodicals, Inc.

Language: Английский

Citations

200
MicroRNAs in regulation of triple-negative breast cancer progression DOI Creative Commons
Dominika Piasecka, Marcin Braun, Radzisław Kordek

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2018, Volume and Issue: 144(8), P. 1401 - 1411

Published: June 19, 2018

Dysregulation of miRNA profile has been associated with a broad spectrum cellular processes underlying progression various human malignancies. Increasing evidence suggests that specific microRNA clusters might be clinical utility, especially in triple-negative breast carcinoma (TNBC), devoid both predictive markers and potential therapeutic targets. Here we provide comprehensive review the existing data on microRNAs TNBC, their molecular targets, putative role invasive particular emphasis epithelial-to-mesenchymal transition (EMT) acquisition stem-cell properties (CSC), regarded as prerequisites for metastasis, significance therapy.PubMed Medline databases were systematically searched relevant literature. 121 articles have selected thoroughly analysed.Several miRNAs EMT/CSC invasion identified significantly (1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 TNBC. miR-221/222 was reported prognostic value TNBC patients.Available suggest play an important biology understanding which should assist disease prognostication therapy.

Language: Английский

Citations

169